Persistence with Anti-Tumor Necrosis Factor Therapies in Patients with Rheumatoid Arthritis: Observations from the RADIUS Registry

Markenson, Joseph A.; Gibofsky, Allan; Palmer, William; Keystone, Edward; Schiff, Michael; Feng, JingYuan; Baumgartner, Scott

doi:10.3899/jrheum.101142

Cited by 80 publications

(56 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It may be related to the prevention of development of autoantibodies to the drug. Similar to the reported findings in PsA, female gender predicts reduced response and lower survival on the biologics in ankylosing spondylitis and rheumatoid arthritis [49][50][51]. The reasons for these gender differences remain unclear.…”

Section: Predictors Of Treatment Responsesupporting

confidence: 75%

Predictors for clinical outcome in psoriatic arthritis – what have we learned from cohort studies?

Eder

Gladman

2014

Expert Review of Clinical Immunology

View full text Add to dashboard Cite

Psoriatic Arthritis (PsA) is a heterogeneous disease that ranges from a mild form of oligoarthritis to destructive polyarthritis. The burden of disease can be severe and comparable to that of rheumatoid arthritis. Identifying predictors of worse outcome may improve the understanding of the underlying mechanisms of the disease and may guide therapeutic management at the individual level. Longitudinal cohort studies identified predictors of long-term outcomes such as joint damage, physical function and work disability in PsA. In general, male gender and lower burden of inflammation at presentation predict better outcome while a delay in diagnosis, disability and joint damage are associated with worse long term outcomes. Several HLA alleles also identify patients who are likely to sustain joint damage.

show abstract

Section: Predictors Of Treatment Responsesupporting

confidence: 75%

Predictors for clinical outcome in psoriatic arthritis – what have we learned from cohort studies?

Eder

Gladman

2014

Expert Review of Clinical Immunology

View full text Add to dashboard Cite

show abstract

“…Similar observational results focusing on long-term effectiveness have been reported in the literature reporting persistence between 22% and 41% by 3 years, but these studies did not observe patients for the length of time ours did [35,36]. A multitude of other observational and registry derived data are available which either followed patients for fewer years [37] or had followed considerably fewer patients [38].…”

Section: Discussionsupporting

confidence: 74%

Long-Term Effectiveness of Adalimumab in Patients with Rheumatoid Arthritis: An Observational Analysis from the Corrona Rheumatoid Arthritis Registry

et al. 2017

View full text Add to dashboard Cite

Introduction Current recommendations for the management of rheumatoid arthritis (RA) focus on a treat-to-target approach with the objective of maximizing long-term health-related quality-of-life in patients with RA. Published studies from randomized clinical trials have reported limited data regarding the long-term efficacy and safety of adalimumab in patients with RA. This study aims to evaluate the long-term (10+ years) persistency and effectiveness of adalimumab in patients with RA in a real-world setting. Methods Included in this study were biologic-naïve adults with RA initiating adalimumab during follow-up enrolled in the Corrona RA registry. More than 10 years of data on persistency of adalimumab and rheumatologist-supplied reasons for discontinuation were examined. Among patients who persisted on adalimumab over the years, clinical [e.g., clinical disease activity index scores (CDAI), physician global assessment, tender joint count, and swollen joint count] and patient-reported outcomes (PRO), such as physical function, pain, fatigue, and morning stiffness, were examined. Results Of 1791 biologic-naive patients treated with adalimumab who had ≥1 follow-up registry visit, 64.1% were still on therapy at 1 year and 10.2% were still on therapy by the end of year 12. Among patients who persisted on adalimumab for at least 1 year (77.1% female, mean age 53.9 years), 67.0% were in low disease activity (LDA)/remission (CDAI ≤10) and had clinically meaningful improvements from baseline in all clinical assessments and PROs. Initial improvements in LDA/remission and in clinical and PRO assessments observed at year 1 were sustained in those patients who remained on adalimumab over 10 years of follow-up. Among patients who discontinued adalimumab, 61.6% were not in LDA/remission and 41.9% switched to another biologic within 12 months after discontinuing adalimumab. Conclusions Real-world data demonstrate a sustained effectiveness of adalimumab in the treatment of RA for patients who remained on therapy for 10 years. Funding Corrona, LLC and AbbVie.

show abstract

“…Similar comparative results were reported from an Italian registry in which ETN was stated to have greater persistence than either ADA or IFX, although the overall persistence rates were higher than those seen in our study for all agents 43 . When switching to a second TNFi, no differences in persistence were noted among the agents 44 . These results suggest a variation in persistence in different populations, but overall persistence rates appear similar to those observed in our study.…”

Section: Discussionmentioning

confidence: 99%

Persistence and Dose Escalation of Tumor Necrosis Factor Inhibitors in US Veterans with Rheumatoid Arthritis

Cannon

DuVall²,

Haroldsen³

et al. 2014

J Rheumatol

View full text Add to dashboard Cite

Objective.Limited evidence exists comparing the persistence, effectiveness, and costs of biologic therapies for rheumatoid arthritis in clinical practice. Comparative effectiveness studies are needed to understand real-world experience with these agents. We evaluated treatment patterns, costs, and effectiveness of tumor necrosis factor inhibitor (TNFi) agents in patients enrolled in the Veterans Affairs Rheumatoid Arthritis (VARA) registry.Methods.Observational data from the VARA registry and linked administrative databases were analyzed. Longitudinal data from VARA patients initiating adalimumab (ADA), etanercept (ETN), or infliximab (IFX) from 2003 (the date all agents were available within the Veteran Affairs) to 2010 were analyzed. Outcomes included Disease Activity Score using 28 joints (DAS28), treatment persistence, dose escalation, and direct costs of drugs and drug administration.Results.For 563 eligible patients, baseline DAS28, DAS28 improvements, and persistence on initial treatment were similar across agents. Fewer patients receiving ETN (n = 5/290; 2%) underwent dose escalation than did patients taking ADA (n = 32/204; 16%) or IFX (n = 44/69; 64%). Annual costs for first course of TNFi therapy were lower for injectable ADA ($13,100 US) and ETN ($13,500 US) than for intravenously administered IFX ($16,900 US).Conclusion.Despite similar persistence and clinical disease activity for these TNFi agents, rates of dose escalation were highest with ADA and IFX. Higher overall costs were noted for IFX without increases in effectiveness.

show abstract

Persistence with Anti-Tumor Necrosis Factor Therapies in Patients with Rheumatoid Arthritis: Observations from the RADIUS Registry

Abstract: In this population, first- and second-course persistence was similar among anti-TNF therapies. First-course discontinuation due to adverse events was lower with etanercept compared with infliximab.

Cited by 80 publications

References 27 publications

Predictors for clinical outcome in psoriatic arthritis – what have we learned from cohort studies?

Predictors for clinical outcome in psoriatic arthritis – what have we learned from cohort studies?

Long-Term Effectiveness of Adalimumab in Patients with Rheumatoid Arthritis: An Observational Analysis from the Corrona Rheumatoid Arthritis Registry

Persistence and Dose Escalation of Tumor Necrosis Factor Inhibitors in US Veterans with Rheumatoid Arthritis

Contact Info

Product

Resources

About